effect of continuous glucose monitoring system on glycemic control in non-insulin-treated elderly people with type 2 diabetes

Conditions: Diabetes Mellitus Type 2

Summary: the goal of this clinical trial is to learn if continuous glucose monitoring system works to improve glucose control in non-insulin-treated older adults with type 2 diabetes. the main questions it aims to answer are: * dose the use of continuous glucose monitoring system improve glucose control in older adults with type 2 diabetes treated with oral antidiabetic drugs only? * dose the use of continuous glucose monitoring system affect psychological outcomes in older adults with type 2 diabetes treated with oral antidiabetic drugs only? researchers will compare continuous glucose monitoring to standard blood glucose monitoring to see if continuous glucose monitoring works better in glucose management. participants will: * wear continuous glucose monitoring every 2 months or standard blood glucose monitoring for 6 months * visit the clinic once every 2 months for follow-up * keep a diary of their blood glucose when continuous glucose monitoring was not used


Eligibility criteria:
inclusion criteria: * age ≥ 60 years at the time of screening; * diagnosed with type 2 diabetes mellitus; * treated with two or more oral antidiabetic drugs for at least 3 months prior to screening, with a stable regimen (i.e., no change in drug classes); * suboptimal glycemic control, defined as hba1c ≥ 7.5% and ≤ 10% at screening or within 30 days prior to screening visit; * willing and able to use the real time-continuous glucose monitoring system; * willing and able to provide written informed consent; * at least 240 hours (10 out of 14 days) of sensor glucose data and self-monitoring of blood glucose frequency ≥2 times per week from the blinded cgm pre- randomization phase. exclusion criteria: * use of insulin or glucagon-like peptide-1 （glp-1） receptor agonists either at screening or within the past 3 months; * use of any cgm device either at screening or within the past 3 months; * participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.; * considered unsuitable for participation by the investigators, including but not limited to individuals with dementia, psychiatric disorders, extreme visual or hearing impairment that would impair ability to use real-time cgm assessed. * expectation that participant will be moving out of the area of the clinical center or have planned surgery during the next 6 months; * current or anticipated acute uses of glucocorticoids (oral, injectable, or iv), that will affect glycemic control (long-term stable glucocorticoid doses are allowed, such as when used for the treatment of rheumatoid arthritis or addison's disease); * stage 4 or 5 renal disease or most recent glomerular filtration rate （gfr） \< 30 ml/min/m2 from local lab within the past 3 months; * participation in any other clinical trial within 1 month prior to screening, or concurrently enrolled, or planning to participate in another trial during the study period.

Keywords: continuous glucose monitoring non-insulin-treated type 2 diabetes in the elderly